Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts

Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has received a consensus rating of "Hold" from the seven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $42.50.Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"NGNE has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Neurogene in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Neurogene in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Neurogene from a "hold" rating to a "sell" rating in a research note on Saturday, December 13th.Get Our Latest Stock Analysis on NeurogeneInstitutional Investors Weigh In On NeurogeneA number of institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Jennison Associates LLC raised its holdings in Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company's stock worth $2,505,000 after buying an additional 59,479 shares during the period. PNC Financial Services Group Inc. lifted its stake in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company's stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. Schroder Investment Management Group acquired a new position in shares of Neurogene in the second quarter worth about $451,000. Finally, Bank of America Corp DE raised its holdings in shares of Neurogene by 81.6% during the second quarter. Bank of America Corp DE now owns 95,401 shares of the company's stock valued at $1,426,000 after acquiring an additional 42,880 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds. Neurogene Price PerformanceShares of NASDAQ:NGNE opened at $17.55 on Monday. The stock has a market cap of $271.85 million, a price-to-earnings ratio of -4.27 and a beta of 1.60. Neurogene has a 12 month low of $6.88 and a 12 month high of $37.27. The stock's 50 day moving average price is $20.76 and its 200 day moving average price is $22.12. Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.27. On average, sell-side analysts expect that Neurogene will post -4.27 EPS for the current year. About Neurogene (Get Free Report)Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions. Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.Further ReadingFive stocks we like better than NeurogeneElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietly“Fed Proof” Your Bank Account with THESE 4 Simple StepsExecutive Order 14330: Trump’s Biggest YetThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Neurogene Right Now?Before you consider Neurogene, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.While Neurogene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here